The American Urological Association announced that Pfizer Oncology is the recipient of the 2023 Health Science Award for its outstanding support of the educational, scientific and research goals of the AUA and the Urology Care Foundation in urologic cancer.
Astellas Pharma Inc. and Pfizer Inc. announced that XTANDI® plus leuprolide significantly reduced the risk of metastasis or death by 58% versus placebo plus leuprolide, as assessed by the primary endpoint of metastasis-free survival, in men with non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence.
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., and MedinCell announced that the U.S. Food and Drug Administration has approved UZEDY extended-release injectable suspension for the treatment of schizophrenia in adults.
Aquavit Holdings announced that it has received FDA clearance to initiate clinical trials for DTX-023 and DTX-024, following its submission of Investigational New Drug Applications.
The joint venture between Walgreens and Prothena to accelerate the approval of an Alzheimer’s treatment is the latest in biotech and retail chain alliances.
Walgreens Launches Partnership with Prothena to Compete with CVS, Walmart Read More »
Longitudinal studies that track patients’ experiences can inform and accelerate the drug approval process for rare diseases.
Natural History Studies Drive Data Sharing, Drug Approval Read More »
As Humira global revenues fall 25%, AbbVie looks to Rinvoq and Skyrizi to fill in the gap. The company also announced it is cutting cystic fibrosis and Crohn’s disease candidates.
Humira Sales Down 25% as AbbVie Cuts Two Programs Read More »
Adults with a disability, Black adults, people with low incomes and those on public insurance were more likely to report going without needed healthcare because of transportation issues, the Urban Institute found.
Without vehicle or viable public transit, 1 in 5 miss needed healthcare: report Read More »
The agency wants to create maximum waiting times for certain appointments in addition to requiring stronger quality monitoring and reporting standards for Medicaid and CHIP managed care plans.
CMS targets Medicaid payment transparency, wait times in new proposed rules Read More »
Oklahoma is the third new state Walmart Health plans to enter next year, along with Missouri and Arizona.
